VANCOUVER, BC / ACCESSWIRE / September 20, 2017 / CVR Medical Corp. (TSX.V:CVM.V) (FRANKFURT: B3BN) (OTCQB: CRRVF) (“CVR Medical“) enters discussions with Key Opinion Leaders in the Chinese cardiovascular health industry, with whom the organization intends to extend membership on the executive board to. The medical and business influence of these leaders will spur the growth of international opportunities for CVR and its “Carotid Stenotic Scan (CSS)” device.
In addition, CVR announces the recent start of negotiations with several prominent Chinese distribution groups. This comes after a successful meeting with the leadership of the Chinese healthcare industry. CVR expects an official letter of intent for distribution in the country to be signed imminently.
“We are very excited to share news of CVR’s expanding global footprint,” states CVR CEO Peter Bakema. “This sets the trajectory of our company for release into the Chinese market in H2 2018, subsequently following our domestic launch. The individuals we are meeting with for executive involvement will hopefully provide valuable insight and access to networks that we anticipate will allow the CSS to reach significant revenue channels in Asia in the event that we enter into definitive distribution agreements for the CSS device. Beyond this, the distribution groups we are in negotiations with have the type of reach and reputation that we will be able to leverage to protect CVR’s IP.”
For additional information on the organization, leadership, and current news please visit the newly launched company website www.CVRMed.com
About CVR Medical
CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the “Joint Venture”). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.
For further information contact:
Brisco Capital Partners Corp.
Scott Koyich, President
Telephone: (403) 262-9888